TITLE

News About the Blues? The Power of Placebo

AUTHOR(S)
Phillips, Barbara A.
PUB. DATE
February 2010
SOURCE
Internal Medicine Alert;2/15/2010, Vol. 32 Issue 3, p17
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
While antidepressants are clearly effective in patients with severe depression, their effects on those with mild or moderate depression may be insignificant.
ACCESSION #
48721707

 

Related Articles

  • Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Sakurai, Hitoshi; Suzuki, Takefumi; Yoshimura, Kimio; Mimura, Masaru; Uchida, Hiroyuki // Psychopharmacology;Aug2017, Vol. 234 Issue 16, p2453 

    Background: Residual symptoms are detrimental to prognosis in major depressive disorder (MDD); however, little is known about the contribution of each residual symptom in predicting outcomes. The objective of this analysis was to identify which individual symptoms, based on self-report and...

  • THE MAP: INTEGRATING INTEGRATIVE MEDICINE. Hyman, Mark A. // Alternative Therapies in Health & Medicine;Jan/Feb2009, Vol. 15 Issue 1, p20 

    The article focuses on functional medicine as a way to integrate integrative medicine. It mentions the various treatments for depression depending on the health practitioner being consulted. Integrative medicine is said to have become a way for healthcare providers who are trained conventionally...

  • Determining when to change to a different antidepressant. Huffman, Grace Brooke // American Family Physician;2/15/1997, Vol. 55 Issue 3, p947 

    Focuses on a study by F.M. Quitkin, et al, published in the `Archives of General Psychiatry,' which tries to determine when patients should be considered unresponsive to antidepressant therapy and should have their treatment changed. `Chronological milestones to guide drug change. When should...

  • New antidepressant drugs called major treatment advances.  // Executive Health's Good Health Report;Oct93, Vol. 30 Issue 1, p3 

    Reports on the acknowledgement of antidepressant drugs Zoloft and Paxil as improvements over previously available antidepressants. Selective serotonin reuptake inhibitors; Effectiveness in treating obsessive compulsive disorders, hypochondriasis and anorexia nervosa; Testing on impulsive behavior.

  • Focus on mirtazapine: A new antidepressant with noradrenergic and specific serotonergic activity. Kehoe, William A.; Schorr, Robert B. // Formulary;Jun96, Vol. 31 Issue 6, p455 

    Focuses on the antidepressant mirtazapine. Chemistry and pharmacology; Serotonic receptors and possible therapeutic applications; Pharmacokinetics; Clinical trials; Adverse effects; Drug interactions; Formulary considerations; Dose and administration. INSET: Formulary considerations..

  • The power of Prozac. Rust, Michael // Insight on the News;09/14/98, Vol. 14 Issue 34, p16 

    Presents information on the antidepressant Prozac. Annual cost of antidepressants in the United States as a result of early death, lost workdays and lowered productivity; Details on Prozac; Investigations being conducted by the Food and Drug Administration on the effort of antidepressants and...

  • Half of antidepressants' benefit attributed to placebo effect.  // Executive Health's Good Health Report;Nov96, Vol. 33 Issue 2, p8 

    Reports that 50 percent of an antidepressant medication's effect can be attributed to the placebo response according to a study made by Doctor Guy Sapirstein from the University of Connecticut. Result of 25 ears' analysis of 3,250 patients with depression.

  • Easy does it. Breu, Joe // Drug Topics;6/24/96, Vol. 140 Issue 12, p37 

    Reports on the Food and Drug Administration's approval of the drug Paxil or paroxetine hydrochloride indicated for panic disorders. Manufacturer; Components; Dosage forms.

  • Vilazodone Hydrochloride Tablets (Viibryd). Elliott, William T.; Chan, James // Internal Medicine Alert;3/15/2011, Vol. 33 Issue 5, p37 

    The article focuses on the introduction of a new antidepressant which had been approved by the Food and Drug Administration (FDA), the Vilazodone or Viibryd in the U.S.

  • Prozac & your libido.  // Joe Weider's Muscle & Fitness;Apr98, Vol. 59 Issue 4, p34 

    Focuses on the effects of taking the antidepressant, Prozac. Classification of Prozac; Identification of symptoms associated with the taking of Prozac; What was noted by J. Raymond Depaulo, a Johns Hopkins psychiatrist.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics